by Admin | May 18, 2020 | Portfolio News
CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc. today announced that it has completed the initial closing of a Series C financing of $85 million to support the commercial launch of the company’s portfolio, which is composed of the latest advances in...
by Admin | May 18, 2020 | Portfolio News
CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc., a company singularly dedicated to addressing unsolved problems in stroke, today announced that Daniel Davis has been appointed as the company’s Chief Operating Officer. Mr. Davis will oversee the...
by Admin | May 11, 2020 | Portfolio News
Grant McFadden has spent over two decades studying the myxoma virus. The ASU virologist grew interested in the myxoma virus because it is extremely deadly in European rabbits but virtually harmless in non-rabbit hosts — including humans. He wanted to figure out why....
by Admin | Apr 27, 2020 | Portfolio News
CEPI to provide initial US$3.5m to Clover Biopharmaceuticals Australia, the wholly-owned subsidiary of Sichuan Clover Biopharmaceuticals, Inc (China) to support preparation and initiation of a phase 1 trial of Clover’s protein-based COVID-19 S-Trimer vaccine in...
by Admin | Mar 19, 2020 | Portfolio News
March 19, 2020 Tanvex BioPharma, Inc., a biotechnology company focused on developing biosimilars, today announced completion of enrollment in its TX05 pivotal clinical trial. TX05 is a proposed biosimilar to Herceptin® (trastuzumab). The global Phase III trial, “A...
by Admin | Feb 25, 2020 | Portfolio News
February 25, 2020 07:00 ET | Source: Allecra Therapeutics GmbH EXBLIFEP demonstrated superiority in the primary endpoint of clinical cure and microbiological eradication at test-of-cure over piperacillin-tazobactam EXBLIFEP safety profile was comparable to...
by Admin | Feb 24, 2020 | Portfolio News
CHENGDU, China, London, UK – 24 February 2020 – Clover Biopharmaceuticals, a China based global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, announced today that it has entered into a research collaboration...
by Admin | Feb 12, 2020 | Portfolio News
ATLANTA, Feb. 12, 2020 /PRNewswire/ — Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases, today announced it has initiated its...
by Admin | Feb 10, 2020 | Portfolio News
CHENGDU, China – 10 February 2020 – Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, announced today that it has successfully produced its trimeric Spike-protein (“S-Trimer”)...
by Admin | Feb 4, 2020 | Portfolio News
Cleveland, Ohio, February 4, 2020 – Thermalin Inc., a privately held biotechnology company with its main laboratories in Cleveland, announces that JDRF, the leading global organization funding type 1 diabetes (T1D) research, presented Thermalin co-founder Michael A....